Crescent Biopharma, Inc. Net Assets

Latest as of June 2026: $163.25 Million USD

Crescent Biopharma, Inc. net assets. Based on the latest financial reports, Crescent Biopharma, Inc. (CBIO) has net assets worth $163.25 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($182.76 Million) and total liabilities ($19.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CBIO net assets growth trend to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$163.25 Million
% of Total Assets	89.33%
Annual Growth Rate	25.48%
5-Year Change	148.78%
10-Year Change	475.09%
Growth Volatility	447.84

Net Assets of Crescent Biopharma, Inc. (2011–2025)

Net assets of Crescent Biopharma, Inc. from 2011 to 2025. This chart illustrates how Crescent Biopharma, Inc.'s net assets have evolved over time, based on quarterly financial data. See net asset quality index of Crescent Biopharma, Inc. to measure how much of total assets are equity-financed.

Annual Net Assets for Crescent Biopharma, Inc. (2011–2025)

The table below shows the annual net assets of Crescent Biopharma, Inc. from 2011 to 2025. For live market cap and overall valuation, see Crescent Biopharma, Inc. stock valuation.

Year	Net Assets	Change
2025-12-31	$203.01 Million	+1411.53%
2024-12-31	$-15.48 Million	-140.29%
2023-12-31	$38.41 Million	-10.52%
2022-12-31	$42.93 Million	-47.39%
2021-12-31	$81.60 Million	-36.36%
2020-12-31	$128.22 Million	-16.85%
2019-12-31	$154.20 Million	-24.95%
2018-12-31	$205.46 Million	+71.65%
2017-12-31	$119.70 Million	+239.09%
2016-12-31	$35.30 Million	-12.78%
2015-12-31	$40.47 Million	-20.34%
2014-12-31	$50.80 Million	+1647.37%
2013-12-31	$2.91 Million	-76.79%
2012-12-31	$12.53 Million	+48.14%
2011-12-31	$8.46 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Crescent Biopharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 11548315500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Crescent Biopharma, Inc. Net Assets Breakdown (December 2025)

Crescent Biopharma, Inc. net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Common Stock	$28.00K	0.01%
Other Components	$374.79 Million	184.62%
Total Equity	$203.01 Million	100.00%

Crescent Biopharma, Inc. Competitors by Market Cap

The table below lists competitors of Crescent Biopharma, Inc. ranked by their market capitalization.

Company	Market Cap
Helgeland Sparebank OL:HELG	$485.19 Million
ForFarmers NV AS:FFARM	$485.27 Million
Beijing Trust Far Tech SHE:300231	$485.50 Million
Prisma Properties ST:PRISMA	$485.54 Million
Semco Technologies Sas PA:ALSEM	$484.91 Million
AngioDynamics Inc NASDAQ:ANGO	$484.83 Million
Changchun Gas Co Ltd SHG:600333	$484.81 Million
Anglo American PLC LSE:AAL	$484.58 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Crescent Biopharma, Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -15,479,000 to 203,012,000, a change of 218,491,000.
Net loss of 153,942,000 reduced equity.
Share repurchases of 177,000 reduced equity.
New share issuances of 321,887,000 increased equity.
Other factors increased equity by 50,723,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-153.94 Million	-75.83%
Share Repurchases	$177.00K	-0.09%
Share Issuances	$321.89 Million	+158.56%
Other Changes	$50.72 Million	+24.99%
Total Change	$-	%

Book Value vs Market Value Analysis

This analysis compares Crescent Biopharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.67x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.29x to 0.67x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	$45.03	$13.06	x
2012-12-31	$1047.35	$13.06	x
2013-12-31	$54.64	$13.06	x
2014-12-31	$275.32	$13.06	x
2015-12-31	$212.89	$13.06	x
2016-12-31	$166.07	$13.06	x
2017-12-31	$407.21	$13.06	x
2018-12-31	$500.59	$13.06	x
2019-12-31	$356.49	$13.06	x
2020-12-31	$280.44	$13.06	x
2021-12-31	$158.60	$13.06	x
2022-12-31	$81.72	$13.06	x
2023-12-31	$60.65	$13.06	x
2024-12-31	$-20.17	$13.06	x
2025-12-31	$19.49	$13.06	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Crescent Biopharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -75.83%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1419.61%
• Asset Turnover: 0.05x
• Equity Multiplier: 1.18x
Recent ROE (-75.83%) is below the historical average (-69.07%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	-72.29%	-160.29%	0.13x	3.42x	$-6.96 Million
2012	29.18%	23.96%	0.83x	1.47x	$2.40 Million
2013	-364.78%	-265.63%	0.76x	1.82x	$-10.90 Million
2014	-21.89%	-74.01%	0.26x	1.13x	$-16.20 Million
2015	-31.55%	-63.62%	0.41x	1.20x	$-16.82 Million
2016	-90.11%	-171945.07%	0.00x	1.20x	$-35.34 Million
2017	-27.80%	0.00%	0.00x	1.07x	$-45.25 Million
2018	-23.50%	0.00%	0.00x	1.05x	$-68.82 Million
2019	-35.09%	0.00%	0.00x	1.09x	$-69.54 Million
2020	-39.80%	-502.09%	0.07x	1.11x	$-63.85 Million
2021	-77.73%	-5468.98%	0.01x	1.16x	$-71.59 Million
2022	-108.76%	-62251.74%	0.00x	1.21x	$-50.98 Million
2023	-96.06%	-368994.20%	0.00x	1.18x	$-40.74 Million
2024	0.00%	0.00%	0.00x	0.00x	$-46.98 Million
2025	-75.83%	-1419.61%	0.05x	1.18x	$-174.24 Million

Industry Comparison

This section compares Crescent Biopharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $154,916,114
Average return on equity (ROE) among peers: -15.75%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Crescent Biopharma, Inc. (CBIO)	$163.25 Million	-72.29%	0.12x	$485.10 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-27.92 Million	0.00%	0.00x	$26.78 Million
Abcellera Biologics Inc (ABCL)	$1.06 Billion	-15.42%	0.29x	$3.53 Billion
Abeona Therapeutics Inc (ABEO)	$-5.83 Million	0.00%	0.00x	$243.03 Million
Acumen Pharmaceuticals Inc (ABOS)	$225.18 Million	-44.68%	0.02x	$16.93 Million
Abpro Holdings, Inc. (ABP)	$-22.46 Million	0.00%	0.00x	$2.00 Million
Absci Corp (ABSI)	$67.00 Million	-21.42%	0.32x	$1.41 Billion
Arbutus Biopharma Corp (ABUS)	$40.92 Million	73.18%	0.29x	$768.65 Million
ABVC Biopharma Inc (ABVC)	$29.08K	-111.02%	1.35x	$26.26 Million
Abivax SA American Depositary Shares (ABVX)	$34.02 Million	-17.32%	0.13x	$7.74 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$182.13 Million	-20.84%	0.04x	$3.54 Billion

About Crescent Biopharma, Inc.

NASDAQ:CBIO USA Biotechnology

Market Cap

$485.10 Million

Market Cap Rank

#12026 Global

#3055 in USA

Share Price

$13.06

Change (1 day)

+1.16%

52-Week Range

$8.94 - $26.98

All Time High

$26.98